Patents by Inventor Midori Shinohara

Midori Shinohara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY HAVING INFECTION-INHIBITING ACTIVITY AGAINST HEPATITIS C VIRUS
    Publication number: 20170107273
    Abstract: An anti-hepatitis C virus E2 protein antibody or antigen-binding antibody fragment thereof has infection inhibiting activity against hepatitis C virus (HCV). An anti-hepatitis C virus E2 protein antibody or antigen-binding antibody fragment thereof includes a certain variable region, which have infection inhibiting activity against hepatitis C virus (HCV) and exhibits an escape mutant emergence suppressive property.
    Type: Application
    Filed: March 20, 2015
    Publication date: April 20, 2017
    Applicant: Japan as Represented by Director-General of National Institute of Infectious Diseases
    Inventors: Takaji Wakita, Midori Shinohara, Hiroshi Yokokawa, Noriko Nakamura
  • Antibody library
    Patent number: 8101553
    Abstract: An antibody library is prepared by selecting a light chain variable region capable of binding to the variable region of heavy chain to reproduce an active conformation and using the same. Because of being capable of maintaining the diversity of the heavy chain variable region at a high ratio in vitro, the antibody library of the present invention is expected as enabling the acquisition of antibodies with various binding activities.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: January 24, 2012
    Assignee: Medical & Biological Laboratories Co., Ltd.
    Inventors: Yoshikazu Kurosawa, Yasushi Akahori, Yoshitaka Iba, Kazuhiko Morino, Midori Shinohara, Motohide Takahashi, Yoshinobu Okuno, Kimiyasu Shiraki
  • Methods for damaging cells using effector functions of anti-EphA4 antibodies
    Patent number: 8003098
    Abstract: The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies.
    Type: Grant
    Filed: February 22, 2007
    Date of Patent: August 23, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Shuichi Nakatsuru, Megumi Yoshikawa, Shinichi Hiroshima, Yoshiro Kishi, Motoki Kuhara, Shiyo Nishida, Midori Shinohara